A novel amplification-based approach to enable gene expression profiling from small clinical tumor specimens

Area of Science:

• Oncology
• Molecular Biology
• Genomics

Background:

• Glioblastoma is a lethal brain cancer with diverse genetic drivers.
• Personalized medicine requires tools to analyze limited tumor samples effectively.
• Understanding glioblastoma's genetic pathways is crucial for targeted therapies.

Purpose of the Study:

• To develop and validate a custom real-time PCR panel for glioma classification.
• To assess the feasibility of using gene expression profiling for personalized glioblastoma care.
• To establish a high-throughput method for analyzing limited clinical brain tumor specimens.

Main Methods:

• A custom 79-target real-time PCR panel (74 mRNA, 5 housekeeping genes) was designed using validated PrimePCR assays.
• RNA extraction, cDNA synthesis, pre-amplification, and SYBR-based qPCR were performed on 19 glioma and 4 normal brain specimens.
• Principal Component Analysis (PCA) was used to analyze gene expression profiles and classify tumor types.

Main Results:

• The developed workflow demonstrated high tolerance to variable RNA quality (RIN 8.5-4) and high sensitivity.
• Accurate semiquantitative analysis was achievable with as little as 3 ng of starting RNA.
• PCA successfully differentiated glioblastoma from low-grade gliomas, with Grade III tumors showing intermediate characteristics.

Conclusions:

• A custom, high-throughput gene expression profiling panel can accurately classify glioma specimens.
• This approach facilitates personalized care by enabling detailed molecular subtyping from limited samples.
• The validated workflow supports the development of targeted therapies for brain tumors.